NCT04115059View on ClinicalTrials.gov

Dasatinib In Waldenström Macroglobulinemia

PHASE1TerminatedINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

November 4, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions

Waldenstrom MacroglobulinemiaDASATINIB

Interventions

DRUG

Dasatinib

Oral, daily, dosing per protocol, once a day for cycle

Trial Locations (1)

02215

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Jorge J. Castillo, MD

OTHER